What's Happening With These Medical Supplies Stocks? - Cooper Cos., TransEnterix, Waters, and West Pharmaceutical Services

Wednesday, April 25, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 24, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on COO, TRXC, WAT, and WST which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has selected the following stocks for assessment this morning: The Cooper Cos. Inc. (NYSE:
COO), TransEnterix Inc. (NYSE AMER: TRXC), Waters Corp. (NYSE: WAT), and West Pharmaceutical Services Inc. (NYSE: WST). These companies are part of the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Cooper Cos.

Pleasanton, California headquartered The Cooper Companies, Inc.'s stock finished Monday's session 0.20% higher at $225.56 with a total trading volume of 297,222 shares. The stock has gained 13.27% in the previous twelve months. The Company's shares are trading below their 50-day moving average by 1.62%. Moreover, shares of Cooper Companies, which operates as a medical device company worldwide, have a Relative Strength Index (RSI) of 50.79.

On April 03rd, 2018, Cooper Cos. announced that CooperSurgical has acquired the assets of The LifeGlobal Group, a global provider of in-vitro fertilization devices, and its affiliates. The transaction is valued at approximately $125 million and is expected to be neutral to earnings per share in FY18 and accretive thereafter, excluding one-time charges and deal-related amortization.

On April 04th, 2018, research firm Goldman initiated a 'Neutral' rating on the Company's stock, with a target price of $231 per share. Get the full research report on COO for free by clicking below at:

www.wallstequities.com/registration/?symbol=COO

TransEnterix

Shares in Morrisville, North Carolina headquartered TransEnterix, Inc. declined 3.68%, ending yesterday's session at $1.83 with a total trading volume of 1.38 million shares. The stock has gained 59.13% over the past twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 6.33% and 8.03%, respectively. Moreover, shares of TransEnterix, which engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery, have an RSI of 52.84. Today's complimentary research report on TRXC is accessible at:

www.wallstequities.com/registration/?symbol=TRXC

Waters

On Monday, Milford, Massachusetts headquartered Waters Corporation's stock saw a rise of 0.67%, to close the day at $209.60. A total volume of 599,315 shares was traded, which was higher than their three months average volume of 503.54 thousand shares. The Company's shares have advanced 32.22% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.52% and 7.83%, respectively. Additionally, shares of Waters, which provides analytical workflow solutions in the US, Europe, Asia, and internationally, have an RSI of 58.04. 

On April 03rd, 2018, Waters Corp. announced the live webcast of its Q1 2018 financial results conference call on April 24th, 2018, at 8:00 a.m. ET. The conference call may be accessed by clicking on "Live Webcast" under the "Investors" section of the Company's website. Register now for your free research document on WAT at:

www.wallstequities.com/registration/?symbol=WAT

West Pharmaceutical Services

Shares in Exton, Pennsylvania headquartered West Pharmaceutical Services, Inc. ended the day 1.07% higher at $91.99. A total volume of 177,526 shares was traded. The stock has gained 12.32% over the last twelve months. The Company's shares are trading above their 50-day moving average by 3.71%. Furthermore, shares of the Company, which manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the US, Germany, France, Other European countries, and internationally, have an RSI of 62.63.

On April 12th, 2018, West Pharma Services announced that it will release its Q1 2018 financial results before the market opens on April 26th, 2018. A conference call will follow at 9:00 a.m. ET to discuss the results and business expectations. A live broadcast of the conference call will be available under the "Investors" section of the Company's website. Click on the link below and see our free report on WST at:

www.wallstequities.com/registration/?symbol=WST

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-medical-supplies-stocks--cooper-cos-transenterix-waters-and-west-pharmaceutical-services-300635230.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store